1
|
Mechelke T, Wittig F, Ramer R, Hinz B. Interleukin-1β Induces Tissue Factor Expression in A549 Cells via EGFR-Dependent and -Independent Mechanisms. Int J Mol Sci 2021; 22:ijms22126606. [PMID: 34205482 PMCID: PMC8235322 DOI: 10.3390/ijms22126606] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2021] [Revised: 05/27/2021] [Accepted: 06/02/2021] [Indexed: 12/03/2022] Open
Abstract
Tissue factor (TF) plays an important role in the progression and angiogenesis of tumor cells. The present study investigated the mechanism of interleukin-1β (IL-1β)-induced TF expression in A549 lung cancer cells. Based on mRNA and protein analyses, including appropriate inhibitor experiments, IL-1β was shown to induce TF expression in a time-dependent manner, mediated by IL-1 receptor-dependent phosphorylation of the mitogen-activated protein kinases (MAPK) p38, p42/44 and c-jun N-terminal kinase (JNK), as well as the Src kinase and the epidermal growth factor receptor (EGFR). Thereby, inhibition of EGFR transactivation by the Src inhibitor PP1 or direct EGFR inhibition by the EGFR tyrosine kinase inhibitor (TKI) erlotinib led to a reduction of IL-1β-induced TF expression and to a suppression of p42/44 MAPK and EGFR activation, while IL-1β-induced p38 MAPK and JNK activation remained unchanged. A knockdown of EGFR by siRNA was associated with decreased IL-1β-mediated p42/44 MAPK activation, which was no longer inhibitable by erlotinib. Concentration-dependent inhibition of IL-1β-induced TF expression was also observed in the presence of gefitinib and afatinib, two other EGFR TKIs. In summary, our results suggest that IL-1β leads to increased TF formation in lung cancer cells via both Src/EGFR/p42/44 MAPK-dependent and EGFR-independent signaling pathways, with the latter mediated via p38 MAPK and JNK.
Collapse
|
2
|
Kamegashira A, Yanase Y, Takahagi S, Saito R, Uchida K, Kawaguchi T, Ishii K, Tanaka A, Ozawa K, Hide M. Histamine‐ or vascular endothelial growth factor‐induced tissue factor expression and gap formation between vascular endothelial cells are synergistically enhanced by lipopolysaccharide, tumor necrosis factor‐α, interleukin (IL)‐33 or IL‐1β. J Dermatol 2020; 47:1293-1300. [DOI: 10.1111/1346-8138.15516] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2020] [Accepted: 06/22/2020] [Indexed: 12/12/2022]
Affiliation(s)
- Akiko Kamegashira
- Departments ofDepartment of DermatologyInstitute of Biomedical and Health SciencesHiroshima University Hiroshima Japan
| | - Yuhki Yanase
- Department of Pharmacotherapy Institute of Biomedical and Health Sciences Hiroshima University Hiroshima Japan
| | - Shunsuke Takahagi
- Departments ofDepartment of DermatologyInstitute of Biomedical and Health SciencesHiroshima University Hiroshima Japan
| | - Ryo Saito
- Departments ofDepartment of DermatologyInstitute of Biomedical and Health SciencesHiroshima University Hiroshima Japan
| | - Kazue Uchida
- Departments ofDepartment of DermatologyInstitute of Biomedical and Health SciencesHiroshima University Hiroshima Japan
| | - Tomoko Kawaguchi
- Departments ofDepartment of DermatologyInstitute of Biomedical and Health SciencesHiroshima University Hiroshima Japan
| | - Kaori Ishii
- Departments ofDepartment of DermatologyInstitute of Biomedical and Health SciencesHiroshima University Hiroshima Japan
| | - Akio Tanaka
- Departments ofDepartment of DermatologyInstitute of Biomedical and Health SciencesHiroshima University Hiroshima Japan
| | - Koichiro Ozawa
- Department of Pharmacotherapy Institute of Biomedical and Health Sciences Hiroshima University Hiroshima Japan
| | - Michihiro Hide
- Departments ofDepartment of DermatologyInstitute of Biomedical and Health SciencesHiroshima University Hiroshima Japan
| |
Collapse
|
4
|
Han D, Li X, Fan WS, Chen JW, Gou TT, Su T, Fan MM, Xu MQ, Wang YB, Ma S, Qiu Y, Cao F. Activation of cannabinoid receptor type II by AM1241 protects adipose-derived mesenchymal stem cells from oxidative damage and enhances their therapeutic efficacy in myocardial infarction mice via Stat3 activation. Oncotarget 2017; 8:64853-64866. [PMID: 29029396 PMCID: PMC5630296 DOI: 10.18632/oncotarget.17614] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2017] [Accepted: 04/21/2017] [Indexed: 12/16/2022] Open
Abstract
The poor survival of cells in ischemic sites diminishes the therapeutic efficacy of stem cell therapy. Previously we and others have reported that Cannabinoid receptor type II (CB2) is protective during heart ischemic injury for its anti-oxidative activity. However, whether CB2 activation could improve the survival and therapeutic efficacy of stem cells in ischemic myocardium and the underlying mechanisms remain elusive. Here, we showed evidence that CB2 agonist AM1241 treatment could improve the functional survival of adipose-derived mesenchymal stem cells (AD-MSCs) in vitro as well as in vivo. Moreover, AD-MSCs adjuvant with AM1241 improved cardiac function, and inhibited cardiac oxidative stress, apoptosis and fibrosis. To unveil possible mechanisms, AD-MSCs were exposed to hydrogen peroxide/serum deprivation to simulate the ischemic environment in myocardium. Results delineated that AM1241 blocked the apoptosis, oxidative damage and promoted the paracrine effects of AD-MSCs. Mechanistically, AM1241 activated signal transducers and activators of transcription 3 (Stat3) through the phosphorylation of Akt and ERK1/2. Moreover, the administration of AM630, LY294002, U0126 and AG490 (inhibitors for CB2, Akt, ERK1/2 and Stat3, respectively) could abolish the beneficial actions of AM1241. Our result support the promise of CB2 activation as an effective strategy to optimize stem cell-based therapy possibly through Stat3 activation.
Collapse
Affiliation(s)
- Dong Han
- Department of Cardiology, State Key Laboratory of Kidney Diseases, Chinese PLA General Hospital, Beijing, China.,Department of Cardiology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China
| | - Xiang Li
- Department of Cardiology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China
| | - Wen-Si Fan
- Department of Cardiology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China
| | - Jiang-Wei Chen
- Department of Cardiology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China
| | - Tian-Tian Gou
- Department of Cardiology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China
| | - Tao Su
- Department of Cardiology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China
| | - Miao-Miao Fan
- Department of Cardiology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China
| | - Meng-Qi Xu
- Department of Cardiology, State Key Laboratory of Kidney Diseases, Chinese PLA General Hospital, Beijing, China
| | - Ya-Bin Wang
- Department of Cardiology, State Key Laboratory of Kidney Diseases, Chinese PLA General Hospital, Beijing, China
| | - Sai Ma
- Department of Cardiology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China
| | - Ya Qiu
- Department of Cardiology, State Key Laboratory of Kidney Diseases, Chinese PLA General Hospital, Beijing, China
| | - Feng Cao
- Department of Cardiology, State Key Laboratory of Kidney Diseases, Chinese PLA General Hospital, Beijing, China.,Department of Cardiology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China
| |
Collapse
|